Detalhe da pesquisa
1.
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
J Allergy Clin Immunol
; 153(2): 479-486.e4, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37866460
2.
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Br J Dermatol
; 186(6): 942-954, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981829